Filing Details
- Accession Number:
- 0000899243-18-027169
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-10-22 16:33:49
- Reporting Period:
- 2018-10-18
- Accepted Time:
- 2018-10-22 16:33:49
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1305253 | Eiger Biopharmaceuticals Inc. | EIGR | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1207833 | L Arnold Oronsky | 2710 Sand Hill Road, Suite 200 Menlo Park CA 94025 | No | No | Yes | No | |
| 1276600 | Khaled Nasr | 2710 Sand Hill Road, Suite 200 Menlo Park CA 94025 | No | No | Yes | No | |
| 1293171 | H Gilbert Kliman | 2710 Sand Hill Road, Suite 200 Menlo Park CA 94025 | No | No | Yes | No | |
| 1443898 | Interwest Partners X Lp | 2710 Sand Hill Road, Suite 200 Menlo Park CA 94025 | No | No | Yes | No | |
| 1460207 | Interwest Management Partners X, Llc | 2710 Sand Hill Road, Suite 200 Menlo Park CA 94025 | No | No | Yes | No | |
| 1553019 | Keval Desai | 2710 Sand Hill Road, Suite 200 Menlo Park CA 94025 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2018-10-18 | 210,800 | $12.07 | 1,388,792 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-10-18 | 26,465 | $12.00 | 1,362,327 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $12.00 to $12.30 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $12.00 to $12.03 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, are Venture Members of IMP10. All Reporting Persons disclaim beneficial ownership of shares of Eiger BioPharmaceuticals, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement.
Billionaire Hedge Funds
